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up of patients who were diagnosed with osteoarthritis between April 2009 and
March 2010 (IMS Disease Analyzer database) The cost includes all medical cost to
the patients in the cohort, and colligated in the Disease Analyzer database (all
consultations with GPs and all resulting drug prescriptions). The evaluated cost is
therefore the annual cost of treatment given to an osteoarthritic patient. RESULTS:
A total of 18,976 patients suffering from osteoarthritis were followed. For these
patients, who had an average age of 66, all consultations with GPs as well as all
resulting drug prescriptions were valued both in terms of societal cost and cost to
health insurance. The average annual cost of disease management by a GP of a
patient suffering from osteoarthritis is therefore valued at €755 societal cost, of
which around 60% (€447) is paid by health insurance. The annual cost of treatment
by a GP of a patient suffering from hip osteoarthritis is significantly lower at the
societal level (€715) than at the health insurance level (€425) compared to patients
suffering from osteoarthritis in the knee or elsewhere, despite their higher age.
CONCLUSIONS: No literary data evaluating the cost of an osteoarthritic patient
currently exists. The closest data is that produced by a COART® France study (Le
Pen and coll, Revue du rhumatisme, December 2005). The prevalence of osteoar-
thritis has been estimated at around 4 million sufferers, even though this figure
may be conservative, we can estimate that the cost of osteoarthritis treatment is
around 3 billion euros. We are sure that further data will be added to existing ones.
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OBJECTIVES: Eighteen percent of patients with rheumatoid arthritis (RA) escape
conventional treatment with Methotrexate and hence biological agents like TNF-
inhibitors are also used. Given a population of patients with severe rheumatoid
arthritis we sort to assess efficacy and safety after failure of DMARD, to estimate
the budget impact of the management of RA in France, to compare between aver-
age annual cost of maintaining a patient under treatment and finally to evaluate
the cost-effectiveness of different available strategies.METHODS:We carried out a
systematic review of randomized control trials conducted between 1999 and 2010
on patients with RA on treatment with one of the biological agents, a quantitative
synthesis of the evidence from random effects mixed treatment comparison was
also done and a Markov model to assess budget impact and cost effectiveness of
different strategies was constructed. We assumed that (i) Response, discontinua-
tion and infection rates where constant over time (ii) model results in terms of cost
and effectiveness were calculated considering 1st line, 2nd line and both (iii) Evolu-
tional trends in market shares for the most effective drug where analyzed. Sensi-
tivity analysis was also performed RESULTS: Biotherapy differed significantly from
DMARDs in terms of ACR 50 response. Given a willingness to pay of 1,715€ Adali-
mumab was efficient, beyond this WTP threshold, Etanercept was the most effec-
tive treatment. A comparison of an increase or decrease in Etanerceptmarket share
shows that the replacement of ETA by more expensive and or/less effective thera-
pies results in a loss estimated at 28million euros over 5years.Considering only 1st
or 2nd line of biotherapy, results in a 4.04% increase of average annual cost of
managing a patient after failure of DMARDs CONCLUSIONS: Substitution of more
expensive biological therapieswithout additional therapeutic benefit to the patient
implies economic loss for society.
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OBJECTIVES: Currently, there are no reliable and validated methods for health
service decision-makers to inform policy on quality care at a systems level. To
address this need, we worked with health administrators, clinicians and research-
ers to create and validate a decision-support tool that service planners can use to
achieve a sustainable, integrated care system for hip and knee OA.METHODS: The
SDmodel reflects the continuumof care, including self-directed, primary, rheuma-
tologic and orthopaedic specialist for hip and knee replacement, acute, rehabilita-
tion, community and surgical follow-up care. The model was developed in four
phases, with phase 1 focusing on demand and flow rates, phase 2 on resources,
phase 3 adding geographical stratification, and phase 4 adding feedback loops. We
populated the model with administrative data from Alberta Health & Wellness
(physician claims, inpatient, and ambulatory data), Survey of Living with Chronic
Diseases in Canada, and clinical/surgical data from Alberta Bone and Joint Health
Institute. Using established principles of SD modeling and an iterative process of
integrated knowledge translation we defined the problem, modeled the system as
a series of stock and flows, and validated themodel. Throughmultiple workshops,
experts from front-line clinical staff and administrators provided input and im-
proved face validity. RESULTS: OA care process diagrams were the preferred for-
mat for developing the model structure. The fully specified SD model has been
validated with end-users and can be used as a decision-support tool to test scenar-
ios and their resulting effects on system performance and costs. CONCLUSIONS:
Based on multiple real-world observational data sources, this SD Model allows
evaluation of alternative clinical and administrative scenarios that reflect antici-
pated changes in health care demands and service. Furthermore, the integrated
knowledge translation process reflects the critical importance of involving clini-
cians and decision-makers when developing a system dynamicsmodel for applied
use.
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OBJECTIVES: To investigate the stability of comparative treatment effects in mul-
tiple treatment comparison meta-analyses where one sparsely informed treat-
ment comparison (i.e., a ‘weak link’) constitute the only available evidence for
linking two separate clusters of treatments.METHODS:We simulatedMTC scenar-
ios where two clusters of well-informed treatment comparisons (i.e., each compar-
ison included a large number of trials and patients) were connected by only one
sparsely informed comparisons, and where the treatments in one cluster were
generally more effective than in the other cluster. As a control, we also simulated
scenarios where the two clusters were connected by one well-informed compari-
son. We varied the degree of heterogeneity and baseline event rates across simu-
lation scenarios. We estimated the probability that the treatments in the cluster of
less effective treatments appeared better than to the treatments of the other clus-
ter, as well as the probability that they appeared similar – either judged by their
associated treatment rankings or by their comparative 95% credible intervals.
RESULTS: Treatment rankings were dominated by spurious treatment effect esti-
mates, and depending on the scenario, yielded misleading inferences in 10-30% of
MTCs. The 95% credible intervals generally had close to nominal coverage. Thus,
the less effective treatments rarely appeared significantly better. Power, however,
was typically lower than 20% to detect the superiority of the better treatments.
CONCLUSIONS: ‘Weak links’ in MTCs can occur over time when, for example, drug
combinations or new classes of drugs are introduced. Although clusters of com-
parisons (e.g., comparisons amongst drugs belonging to the same class) may be
well-informed by several trials and randomized patients, the overall comparative
effectiveness between all considered treatments may hinge primarily on a few
‘weak links’. When this happens it is important to recognize the statistical limita-
tions demonstrated in our simulations.
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OBJECTIVES: Descrete Choice (DC) is a proliferative connective tissue disorder in
which fingers bend towards the palm and cannot be fully extended. DC’s quality of
life impact varies according to number/severity of affected fingers. To overcome
this heterogeneity, DCE methods were used to estimate DC utilities.METHODS: A
sample of theUnited Kingdomgeneral populationwas invited, via Internet, to state
preferences for varying hypothetical DC hand severity, defined using a combina-
tion of contractures (0°, 45° or 90°) in 8 joints [proximal interphalangeal (PIP) and
metacarpophalangeal (MCP) joints of the index, middle, ring and little fingers].
Using an optimal DCE design, 56 DC hands were selected from the 6,561 (38)
possible profiles. Right-handed, left-handed, and ambidextrous respondents were
asked to compare 10 randomly selected profile pairs and to indicate which hand,
within each pair, was preferable. To facilitate consistent comparisons, anatomi-
cally precise digital hand drawings were used. To anchor preferences on a tradi-
tional 0-1 utility scale, participants indicated how having themost severe hand (all
joints bent 90°) would affect their EQ-5D-5L profile. Unaffected hands were as-
sumed to have a utility of 1.0. Conditional logistic models were used to estimate
indirect utility weights for the joints, and were subsequently rescaled to EQ-5D-5L.
RESULTS: A total of 1745 participants provided valid and complete responses. An-
choring utilities for the most severe dominant, non-dominant, and ambidextrous
hands were 0.4909, 0.5688 and 0.6343, respectively. For a dominant hand with 90°
contracture in MCP joints of the ring and little fingers, the estimated utility was
0.8848. If only the MCP joint of the ring finger was affected, the utility was 0.9477
and increased to 0.9738 if the contracture was 45° instead. CONCLUSIONS:DCmay
be associated with relatively large utility decrements. The model provides a con-
venient and useful tool to estimate any preference-based DC utilities for clinical
and economic appraisals.
PMS92
ADAPTATION AND VALIDATION OF AN INDIAN VERSION OF THE HEALTH
RELATED QUALITY OF LIFE SCALE (IND-HAQ) IN INDIAN PATIENTS WITH
RHEUMATOID ARTHRITIS
Khera K1, Nagappa AN1, Balakrishnan R2, Sharma S3
1Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India, 2University of Michigan,
MI, MI, USA, 3GuruNanak Dev University, Jalandhar, India
OBJECTIVES: To test the validity and reliability of a newly developed Rheumatoid
Arthritis (RA) quality of life instrument: the Indian Health-Related Quality of Life
Instrument (IND-HAQ).METHODS: A total of 60 rheumatoid arthritis (RA) patients
were asked to complete the IND-HAQ at 2 time points (4 weeks apart). Patients also
completed the Stanford Health Assessment Questionnaire (PROMIS-HAQ) at the
second time point. PROMIS-HAQ scores were used to assess the validity of the
IND-HAQ. Besides the HAQ, the other outcome measures constituting the ACR
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